Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Interest Expenses: 2009-2024

Historic Interest Expenses for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $33.0 million.

  • Ironwood Pharmaceuticals' Interest Expenses fell 10.46% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.8 million, marking a year-over-year increase of 3.78%. This contributed to the annual value of $33.0 million for FY2024, which is 52.73% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Interest Expenses stood at $33.0 million for FY2024, which was up 52.73% from $21.6 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Interest Expenses registered a high of $33.0 million during FY2024, and its lowest value of $7.6 million during FY2022.
  • Moreover, its 3-year median value for Interest Expenses was $21.6 million (2023), whereas its average is $20.8 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Interest Expenses crashed by 75.61% in 2022, and later skyrocketed by 184.67% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Interest Expenses (Yearly) stood at $29.5 million in 2020, then climbed by 5.67% to $31.1 million in 2021, then tumbled by 75.61% to $7.6 million in 2022, then surged by 184.67% to $21.6 million in 2023, then soared by 52.73% to $33.0 million in 2024.